# United States Photodynamic Therapy Market > United States Photodynamic Therapy Market Size, Growth Research Report By Product Type (Photosensitizer Drugs and Photodynamic Therapy Devices), By Light Source (Lasers, Light Emitting Diodes (LEDs), Lamps, and Others), By Application (Cancer, Actinic Keratosis (AK), Psoriasis, Acne, and Others), By End User (Hospitals, Cancer Treatment Centers, Cosmetic and Dermatology Clinics, and Others), – Competitor Industry Analysis and Trends Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.84% - **2024:** $ 320.4 Million - **2025:** $ 355.32 Million - **2035:** $ 900 Million - **Key Players:** Photocure ASA (NO), Merck & Co., Inc. (US), Galderma S.A. (CH), Sensus Healthcare, Inc. (US), DUSA Pharmaceuticals, Inc. (US), Aduro Biotech, Inc. (US), Curelight Ltd. (IL), OncoSec Medical Incorporated (US) **Report ID:** MRFR/Pharma/19151-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/united-states-photodynamic-therapy-market-20700 --- ## Market Summary ## **United States Photodynamic Therapy Market Overview** As per MRFR analysis, the US Photodynamic Therapy Market Size was estimated at 1,895.17 (USD Billion) in 2024. The US Photodynamic Therapy Market Industry is expected to grow from 2,039.24 (USD Billion) in 2025 to 3,943.23 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.60% during the forecast period (2025 - 2034). Rising incidences of skin disorders and cancer and growing government investment in research and development are the main market drivers anticipated to propel the photodynamic therapy market in the United States.  Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **United States Photodynamic Therapy Market Trends** ### **Increasing demand for the photosensitizer drugs is driving the market growth.** Chemical components or medications known as photosensitizers are used with light to treat various cancer types. The cancer cells are destroyed by photosensitizers, which absorb light and transform into a different form. The regulatory bodies of the world have approved a large number of medications to treat cancer. In September 2021, for example, Soligenix, Inc. reported that the FDA's Office of Orphan Products Development had designated the active ingredient hypericin for use as an orphan drug for the treatment of T-cell lymphoma, expanding the target population beyond cutaneous T-cell lymphoma. Increasing R&D spending by industry participants to find novel photosensitizers that enhance clinical outcomes is projected to propel the growth of the market CAGR during the projected period. Because of technological developments that have minimized side effects and increased public awareness, photodynamic treatment devices are expected to grow profitably. Increased segmental expansion in the market is anticipated due to the rise in cancer cases and the expanding use of photodynamic therapy as a treatment. According to the National Board of Health and Welfare, the United States Cancer Registry received reports of 68,318 malignant tumors from 62,555 individuals in 2020. The number of cancer-related deaths was significantly lower than the number of people who were diagnosed with the disease. Over the forecast period, the segment is expected to rise due to the increasing application of photodynamic treatment for various cancers, including lung and breast cancer.  Additionally, because minimally invasive procedures involve less discomfort, require shorter recovery periods, and have fewer consequences, patients frequently favor them over standard surgical methods. PDT, a minimally invasive technique, supports this preference. Compared to conventional surgical procedures, minimally invasive therapies typically have a smaller financial impact on healthcare. Patients and healthcare professionals find this financial benefit attractive, encouraging PDT's growing use. Patients who receive less invasive treatments can typically return to their regular activities sooner because of their faster recovery. PDT enhances patients' quality of life by its tailored approach, which minimizes damage to healthy tissues. Thus driving the Photodynamic Therapy market revenue. ## **United States Photodynamic Therapy Market Segment Insights** ### **Photodynamic Therapy Product Type Insights** Based on Product Type, the United States Photodynamic Therapy market segmentation includes photosensitizer drugs and photodynamic therapy devices. The photosensitizer drugs segment mostly dominated the market. Photosensitizer medications ensure a more accurate and targeted course of treatment because they are designed to concentrate in target cells selectively. This selectivity decreases the possibility of damage to the nearby healthy tissues. The positive patient outcomes and expanding acceptance of photodynamic therapy in clinical practice have led to a rise in the use of photosensitizer drugs. Given the widespread use of photodynamic therapy in treating many cancers, photosensitizer drugs are a crucial component of cancer therapy. Accurately targeting and eliminating cancer cells has been a major factor in the popularity of photosensitizer-based photodynamic treatment. The photodynamic therapy devices category is anticipated to be the fastest growing. Photodynamic therapy is used to treat several dermatological issues, including actinic keratosis, acne, and specific kinds of skin lesions. It works very well to improve the skin's texture and treat precancerous skin disorders. Photodynamic therapy is used in ophthalmology for [age-related macular degeneration](../../../reports/age-related-macular-degeneration-market-5736) (AMD) and other eye disorders. Photosensitizing chemicals are injected to target and eliminate aberrant blood vessels in the afflicted eye, and light is delivered to target and eliminate aberrant blood vessels in the afflicted eye. **Figure 1: United States Photodynamic Therapy Market, by Product Type, 2023 & 2032 (USD Billion)** **** _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ ### **Photodynamic Therapy Light Source Insights** Based on Light Source, the United States Photodynamic Therapy market segmentation includes lasers, light-emitting diodes (LEDs), lamps, and others. The lasers category earned the greatest revenue. The accurate and regulated application of light energy using lasers is necessary to initiate photosensitizing photodynamic treatment (PDT) medications. This precision lessens damage to neighboring healthy tissues while successfully treating the targeted location. Because of their adaptability, lasers can be used for various PDT operations and are employed in a wide range of medical applications. Because laser-based photodynamic therapy (PDT) is concentrated, it has fewer side effects and issues than various other treatment techniques. For several medical conditions, laser-based PDT is the superior choice. The market for photodynamic therapy light emitting diodes (LEDs) segment is anticipated to grow fastest during the forecast period. In general, LED technology is less expensive than conventional laser systems. Demand for LED-based PDT devices rises because of their cost, which enables a wider range of healthcare facilities to use them. ### **Photodynamic Therapy Application Insights** Based on Application, the United States Photodynamic Therapy market segmentation includes cancer, actinic keratosis (AK), [psoriasis](../../../reports/psoriasis-treatment-market-2769), acne, and others. The cancer category has the largest market share. It is anticipated to increase dramatically shortly. Cancer is a significant and pervasive health risk worldwide. The need for targeted and effective therapeutic techniques, such as photodynamic therapy, has increased due to the rising incidence of many types of cancer. Additionally, photodynamic therapy has shown promising results in treating several malignancies. It kills cancer cells by using compounds that are photosensitized to light. As patients and medical professionals become more informed about novel and alternative cancer treatments, the need for photodynamic therapy has increased. This is particularly relevant for certain cancer types where PDT has demonstrated potential. The acne category is expected to have the quickest rate. The customized technique known as photodynamic treatment targets and eliminates acne-causing bacteria and sebaceous glands by using light to activate photosensitizing compounds. In addition, patients are increasingly turning to alternatives to traditional acne treatments, including topical creams and oral medications, which may have unfavorable side effects or be ineffective. Because PDT is non-invasive, has little risk of side effects, and can be tailored to each patient's skin type, it is a popular choice for those seeking effective acne therapy. ### **Photodynamic Therapy End User Insights** Based on End Users, the United States Photodynamic Therapy market segmentation includes hospitals, cancer treatment centers, cosmetic and dermatology clinics, and others. The hospitals category has the largest market share. Hospitals provide a controlled and established clinical setting necessary for photodynamic therapy administration. PDT treatments are guaranteed safe and effective because hospital infrastructure and facilities are designed to handle medical procedures. For photodynamic therapy, specialized equipment, including light sources and diagnostic instruments, is required. The availability of PDT equipment is constant because hospitals usually have access to state-of-the-art medical technology. The cosmetic and dermatology clinics category is expected to have the quickest rate. There is an increasing need for cosmetic procedures to address skin conditions and enhance attractiveness. Dermatology and cosmetic clinics offer PDT as an effective, non-invasive treatment option for various skin problems, attracting a larger patient base seeking cosmetic solutions. The benefits of PDT for skin rejuvenation and therapy are now better understood, which has led to increased patient education. Dermatology and cosmetic surgery clinics are essential for the diffusion of knowledge, which helps to explain why PDT treatments are growing in popularity and driving the segment's rise in the photodynamic therapy market. ### **Photodynamic Therapy Country Insights** The presence of major companies in the United States market, the rise in demand for new biologics to treat cancer, the rapid adoption of photodynamic therapy, and the introduction of new products by industry participants. The actinic keratosis market in the United States is experiencing growth due to several factors, including an increase in the number of cosmetologists offering photodynamic therapy, a rise in product approvals by the US Food and Drug Administration, and a surge in the use of photodynamic therapy for this purpose. In December 2021, Biofrontera Inc. announced that the first participant in a Phase 1 study assessing the safety and tolerability of photodynamic therapy (PDT) for actinic keratosis (AK) had been enrolled. PDT involves utilizing three tubes of Ameluz in conjunction with the company's BF-RhodoLED XL lamp. It is anticipated that these product approvals will propel the US market. ## **United States Photodynamic Therapy Key Market Players & Competitive Insights** Major industry players are expected to invest extensively in R&D to extend their product lines, which would drive additional growth in the market for photodynamic therapy systems. Players in the industry launch a variety of tactical measures to increase their market penetration in parallel with these significant developments in the market. These actions consist of contracts, mergers and acquisitions, increased investments, cooperation with other businesses, and new product types of light sources. To grow and thrive in a more competitive and dynamic market, it must provide reasonably priced products. This is because of the photodynamic therapy industry. Major United States Photodynamic Therapy market players are attempting to increase market demand by investing in research and development operations, including Gladerma S.A., Biofrontera, Novartis AG, Lumibird (Quantel Medical), Theralase Technologies Inc., Quest Pharmatech, Inc., Hologic, Inc., Biolitec AG, Photocure ASA, IPG Photonics Corporation, Sun Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc. ### **Key Companies in the United States Photodynamic Therapy market include** - [Gladerma S.A.](https://www.galderma.com/news/galderma-unveil-ground-breaking-data-across-its-leading-dermatology-portfolio-and-showcase) - Biofrontera - Novartis AG - Lumibird (Quantel Medical) - Theralase Technologies Inc. - Quest Pharmatech, Inc. - Hologic, Inc. - Biolitec AG - Photocure ASA - IPG Photonics Corporation - Sun Pharmaceutical Industries Ltd. - Valeant Pharmaceuticals International, Inc. ## **Photodynamic Therapy Industry Developments** **January 2023:**The international biopharmaceutical company Biofrontera AG announced that the U.S. Patent Office (USPTO) had sent a notice of allowance for the application "Photodynamic therapy comprising two light exposures at different wavelengths" (US Appl. No. 17/269,816) to its wholly owned subsidiary Biofrontera Bioscience GmbH. This patent covers several inventions related to a novel lighting technique for Photodynamic Therapy (PDT) treatment of dermatological skin disorders. **March 2022:**The US patent No. 11,235,169 for the BF-RhodoLED XL illumination device was previously issued to Biofrontera Inc. The company has announced that the device is now listed in the FDA publication "Approved Drug Products with Therapeutic Equivalency Evaluations, or the Orange Book. ## **United States Photodynamic Therapy Market Segmentation** ### **Photodynamic Therapy Product Type Outlook** - Photosensitizer Drugs - Photodynamic Therapy Devices **Photodynamic Therapy ****Light Source ****Outlook** - Lasers - Light Emitting Diodes (LEDs) - Lamps - Others ### **Photodynamic Therapy ****Application ****Outlook** - Cancer - Actinic Keratosis (AK) - Psoriasis - Acne - Others ### **Photodynamic Therapy ****End User ****Outlook** - Hospitals - Cancer Treatment Centers - Cosmetic and Dermatology Clinics - Others ## Market Drivers ### Rising Incidence of Skin Cancer The US Photodynamic Therapy Market is experiencing growth due to the increasing incidence of skin cancer, particularly melanoma. According to the American Cancer Society, skin cancer remains the most common form of cancer in the United States, with over 5 million cases treated annually. This alarming trend has prompted healthcare providers to seek effective treatment options, including photodynamic therapy, which offers a minimally invasive approach with fewer side effects compared to traditional methods. As awareness of skin cancer rises, patients are more likely to explore innovative treatments, thereby driving demand within the US Photodynamic Therapy Market. Furthermore, the potential for photodynamic therapy to be used in combination with other treatments may enhance its appeal, suggesting a promising future for this sector. ### Advancements in Photodynamic Agents Innovations in photodynamic agents are significantly influencing the US Photodynamic Therapy Market. Recent developments have led to the creation of more effective and targeted photosensitizers, which enhance the efficacy of photodynamic therapy. For instance, new agents are being designed to selectively accumulate in cancerous tissues, thereby minimizing damage to surrounding healthy cells. This advancement not only improves treatment outcomes but also reduces recovery times for patients. As a result, healthcare providers are increasingly adopting these advanced agents, contributing to the growth of the US Photodynamic Therapy Market. The ongoing research and development in this area indicate a strong potential for further enhancements, which could lead to broader applications of photodynamic therapy in various cancer types. ### Regulatory Approvals and Guidelines The US Photodynamic Therapy Market is positively impacted by regulatory approvals and guidelines that facilitate the adoption of photodynamic therapy. The US Food and Drug Administration (FDA) has approved several photodynamic agents and devices for clinical use, which has bolstered confidence among healthcare providers and patients alike. These approvals not only validate the safety and efficacy of photodynamic therapy but also encourage further research and development in the field. Additionally, the establishment of clinical guidelines by professional organizations promotes the standardization of treatment protocols, ensuring that patients receive optimal care. As regulatory support continues to evolve, it is expected that the US Photodynamic Therapy Market will expand, with more healthcare facilities integrating photodynamic therapy into their cancer treatment offerings. ### Increased Investment in Cancer Treatment The US Photodynamic Therapy Market is benefiting from increased investment in cancer treatment research and development. Government initiatives, such as the National Cancer Institute's funding programs, are aimed at fostering innovation in cancer therapies, including photodynamic therapy. This financial support encourages collaboration between academic institutions and industry players, leading to the development of novel treatment modalities. Moreover, venture capital investments in biotechnology firms focused on photodynamic therapy are on the rise, reflecting a growing confidence in the market's potential. As funding continues to flow into this sector, it is likely that advancements in photodynamic therapy will accelerate, further solidifying its position within the US Photodynamic Therapy Market. ### Growing Demand for Minimally Invasive Procedures The US Photodynamic Therapy Market is witnessing a surge in demand for minimally invasive procedures, driven by patient preferences for less traumatic treatment options. Photodynamic therapy, which utilizes light to activate photosensitizing agents, offers a non-surgical alternative for treating various cancers, particularly skin and superficial tumors. Patients are increasingly seeking therapies that promise quicker recovery times and reduced pain, making photodynamic therapy an attractive option. This shift in patient expectations is prompting healthcare providers to incorporate photodynamic therapy into their treatment protocols, thereby expanding its presence in the US Photodynamic Therapy Market. As the trend towards minimally invasive treatments continues, the market is likely to experience sustained growth. ## Future Outlook The US Photodynamic Therapy Market is projected to grow at a 9.84% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising awareness of minimally invasive treatments. **New opportunities:** - Development of targeted photodynamic agents for specific cancer types. - Expansion of telemedicine platforms for remote photodynamic therapy consultations. - Partnerships with healthcare providers for integrated photodynamic therapy services. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in innovative cancer treatment solutions. ## Segment Insights ### By Application: Oncology (Largest) vs. Dermatology (Fastest-Growing) In the US Photodynamic Therapy Market, the application segments showcase a diverse distribution with oncology leading prominently. Oncology is recognized for its significant share due to the increasing prevalence of cancer, which drives demand for innovative treatment options. Following closely, dermatology is experiencing rapid growth, fueled by the rising incidence of skin disorders and the growing awareness of photodynamic therapy benefits. This distinction indicates a strong adoption of these therapies among healthcare providers and patients alike, especially in detecting and treating cancerous cells. The growth trends within these segments are influenced by technological advancements and increased research funding dedicated to photodynamic therapy's efficacy. Additionally, favorable regulatory frameworks and heightened patient acceptance further bolster these applications. As oncology remains the most substantial segment, dermatology's swift ascent highlights the shift towards non-invasive treatments, potentially reshaping the therapeutic landscape over the coming years. Oncology (Dominant) vs. Dermatology (Emerging) Oncology remains the dominant application in the US Photodynamic Therapy Market, characterized by its strong focus on treating various types of cancer, including skin, lung, and esophageal cancers. This dominance is attributed to the therapy's ability to selectively target cancer cells while minimizing damage to surrounding healthy tissue. The emergence of dermatology as a key player showcases the market's evolution, with increasing emphasis on treating skin lesions, acne, and psoriasis. The rapid adoption of photodynamic therapy in this field is further supported by advancements in laser technology and a growing preference for minimally invasive procedures among patients. Together, these segments illustrate the shifting dynamics and expanding opportunities within the Photodynamic Therapy landscape. ### By Type of Photosensitizer: Porphyrins (Largest) vs. Phthalocyanines (Fastest-Growing) Within the US Photodynamic Therapy Market, the distribution of market share among various types of photosensitizers reveals a clear hierarchy. Porphyrins remain the largest segment, driven by their extensive historical use and proven efficacy in clinical applications. Phthalocyanines, while not the largest current segment, are rapidly gaining traction due to their enhanced absorption characteristics and versatility in treatment applications. This dynamic landscape indicates a robust competitive environment among these leading photosensitizer types. As the market evolves, growth trends are notably influenced by ongoing research and development in photosensitizer formulations. Increased awareness and adaptability of treatment approaches, particularly in cancer therapies, are propelling Phthalocyanines into the forefront as the fastest-growing segment. Additionally, the rising demand for personalized medicine and combination therapies is further supporting the introduction and acceptance of new photosensitizer options, augmenting the therapeutic capabilities of Photodynamic Therapy across various medical specializations. Porphyrins (Dominant) vs. Phthalocyanines (Emerging) Porphyrins have established themselves as the dominant type of photosensitizer in the US Photodynamic Therapy Market, primarily attributed to their long-standing use and clinical validation. These compounds demonstrate excellent light-absorbing properties and a favorable profile for use in a variety of cancers, making them the preferred choice for many healthcare providers. Conversely, Phthalocyanines are emerging as a competitive alternative, noted for their superior stability and potential in treating a broader spectrum of diseases. Their advanced photophysical properties allow for deeper tissue penetration and improved therapeutic outcomes, thus capturing the attention of researchers and clinicians alike. As innovation continues in this space, Phthalocyanines are expected to gain a larger share, creating opportunities for novel applications in photodynamic therapy. ### By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing) In the US Photodynamic Therapy Market, hospitals hold the largest share of end users due to their extensive resources and specialized personnel. They provide a wide range of services, incorporating advanced photodynamic therapy technologies in treating various conditions, including cancer and dermatological disorders. Ambulatory surgical centers, while smaller in share, are rapidly gaining traction as they offer cost-effective and convenient treatment options which appeal to patients requiring outpatient services. As the demand for minimally invasive procedures grows, the role of ambulatory surgical centers as a fast-growing segment is becoming more pronounced. These centers benefit from increased patient preference for outpatient care, advancements in photodynamic therapy techniques, and favorable reimbursement policies. This trend is expected to drive significant growth in this segment, allowing it to potentially equalize the market share with hospitals in the foreseeable future. Hospitals (Dominant) vs. Dermatology Clinics (Emerging) Hospitals are positioned as the dominant end user in the US Photodynamic Therapy Market, primarily due to their comprehensive treatment capabilities and access to a broad range of photodynamic therapy technologies. They typically offer extensive resources, including multidisciplinary teams that enhance patient care and treatment outcomes. Dermatology clinics, while emerging, have carved out a niche by specializing in skin-related conditions and leveraging targeted photodynamic therapies for issues such as acne, psoriasis, and precancerous lesions. Their growth is fueled by increasing awareness of skin health and advancements in technology that streamline treatment processes, attracting patients seeking specialized care. As the market evolves, these clinics are likely to expand their offerings and further establish their position in the therapy landscape. ### By End User: Hospitals (Largest) vs. Cancer Treatment Centers (Fastest-Growing) In the United States Photodynamic Therapy Market, hospitals currently hold the largest share, driven by their extensive resources and infrastructure to facilitate comprehensive treatment options. Cancer treatment centers, however, are rapidly gaining ground, capturing an increasing share of the market as they specialize in advanced cancer care and innovative treatments that appeal to a targeted patient demographic. Both segments are crucial, but the distinction in their patient care approaches influences market dynamics significantly. The growth trends for these segments are shaped by rising incidences of cancer and skin disorders that necessitate effective therapies. Furthermore, increasing adoption of minimally invasive treatment options among patients is benefiting hospitals and cancer treatment centers equally, with a notable surge in awareness driving demand for photodynamic therapy across diverse clinical settings. Hospitals (Dominant) vs. Cancer Treatment Centers (Emerging) Hospitals represent a dominant segment in the United States Photodynamic Therapy Market, primarily due to their capability to offer a wide range of medical services and access to advanced technologies. They benefit from established patient referral systems and are adept at managing complex cases. In contrast, cancer treatment centers are emerging as a vital segment, focusing specifically on oncology care. These centers typically employ specialized medical teams, creating personalized treatment plans that cater to individual patient needs. Their targeted approach, combined with an emphasis on cutting-edge research and therapies, places them in a strong competitive position. This interplay between dominant hospitals and emerging cancer treatment centers highlights the evolving landscape of photodynamic therapy, where specialized care is becoming increasingly essential. ## Regional Market Share Analysis ### North America : Leading Market for Innovation The North American market for photodynamic therapy (PDT) is primarily driven by increasing incidences of skin cancer and other dermatological conditions. The U.S. holds the largest share of the market, accounting for approximately 70%, followed by Canada with around 15%. Regulatory support from the FDA for PDT products has further catalyzed market growth, enhancing patient access to innovative treatments. The rising awareness of PDT's benefits among healthcare providers and patients is also a significant growth driver. In this region, the competitive landscape is characterized by the presence of key players such as DUSA Pharmaceuticals Inc, Merck & Co Inc, and Hologic Inc. These companies are actively involved in research and development to enhance PDT technologies. The U.S. market is also witnessing collaborations between pharmaceutical companies and research institutions, aimed at improving treatment efficacy and expanding applications of PDT. This dynamic environment positions North America as a leader in The United States Photodynamic Therapy Market. ### Europe : Emerging Market with Potential Europe is witnessing a growing interest in photodynamic therapy, driven by increasing healthcare expenditure and advancements in medical technologies. The region is characterized by a diverse regulatory landscape, with countries like Germany and the UK leading the market. Germany holds approximately 25% of the European market share, while the UK follows closely with around 20%. The European Medicines Agency (EMA) has been instrumental in approving new PDT products, which has spurred market growth and innovation in treatment options. Leading countries in Europe are focusing on enhancing their healthcare infrastructure to support the adoption of PDT. The competitive landscape includes key players such as Galderma S.A. and Photocure ASA, which are investing in clinical trials to expand the applications of PDT. Additionally, partnerships between healthcare providers and pharmaceutical companies are fostering innovation, making Europe a promising market for photodynamic therapy in the coming years. ### Asia-Pacific : Rapidly Growing Market The Asia-Pacific region is rapidly emerging as a significant market for photodynamic therapy, driven by rising healthcare awareness and increasing incidences of skin diseases. Countries like Japan and Australia are leading the market, with Japan holding approximately 30% of the regional share, followed by Australia at around 20%. The regulatory environment is becoming more favorable, with governments promoting advanced treatment options, which is expected to further boost market growth in the coming years. The competitive landscape in Asia-Pacific is evolving, with local and international players entering the market. Companies such as Sientra Inc and Aclaris Therapeutics Inc are expanding their presence in this region. The focus on research and development is increasing, with many firms investing in innovative PDT technologies to cater to the growing demand. This trend is expected to create numerous opportunities for growth and collaboration in the Asia-Pacific PDT market. ### Middle East and Africa : Untapped Market Potential The Middle East and Africa region presents untapped potential for photodynamic therapy, driven by increasing healthcare investments and a growing awareness of advanced treatment options. Countries like South Africa and the UAE are at the forefront, with South Africa holding approximately 15% of the regional market share. The regulatory landscape is gradually improving, with local health authorities beginning to recognize the benefits of PDT, which is expected to catalyze market growth in the near future. The competitive landscape is still developing, with a few key players like Bausch Health Companies Inc and Curelight Ltd making strides in the region. The focus on enhancing healthcare infrastructure and increasing access to innovative treatments is crucial for market expansion. As awareness of PDT grows, more healthcare providers are likely to adopt these therapies, paving the way for future growth in the Middle East and Africa. ## Competitive Benchmarking The Photodynamic Therapy Market is currently characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for minimally invasive treatment options. Key players such as Merck & Co., Inc. (US), DUSA Pharmaceuticals, Inc. (US), and OncoSec Medical Incorporated (US) are actively shaping the market through strategic initiatives. Merck & Co. (US) has positioned itself as a leader in innovation, focusing on the development of novel photodynamic agents that enhance treatment efficacy. Meanwhile, DUSA Pharmaceuticals, Inc. (US) emphasizes regional expansion and partnerships to broaden its market reach, particularly in dermatological applications. OncoSec Medical Incorporated (US) is leveraging digital transformation to optimize its clinical trials and patient engagement strategies, thereby enhancing its competitive edge. The business tactics employed by these companies reflect a concerted effort to localize manufacturing and optimize supply chains, which are crucial in a moderately fragmented market. This competitive structure allows for a diverse range of products and services, fostering innovation while also presenting challenges in terms of market share and customer loyalty. The collective influence of these key players is significant, as they navigate regulatory landscapes and adapt to evolving consumer preferences. In December 2025, Merck & Co., Inc. (US) announced a collaboration with a leading research institution to develop a next-generation photodynamic therapy platform aimed at treating various cancers. This strategic move is likely to enhance Merck's portfolio and solidify its position as a frontrunner in the market, as it seeks to integrate cutting-edge research with practical applications in oncology. In November 2025, DUSA Pharmaceuticals, Inc. (US) launched a new photodynamic therapy device specifically designed for the treatment of actinic keratosis. This product introduction not only expands DUSA's product line but also demonstrates its commitment to addressing unmet medical needs in dermatology. The launch is expected to drive revenue growth and strengthen DUSA's market presence. In October 2025, OncoSec Medical Incorporated (US) reported a successful Phase 2 clinical trial for its photodynamic therapy treatment in combination with immunotherapy for melanoma patients. This achievement underscores the potential of combining therapies to enhance patient outcomes, positioning OncoSec as a key player in the evolving landscape of cancer treatment. As of January 2026, the competitive trends in the Photodynamic Therapy Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and improving patient care. Looking ahead, the competitive differentiation in this market is likely to shift from price-based competition to a focus on technological advancements, innovative treatment solutions, and reliable supply chains, reflecting a broader trend towards value-based healthcare. ## Recent News & Developments **January 2023:**The international biopharmaceutical company Biofrontera AG announced that the U.S. Patent Office (USPTO) had sent a notice of allowance for the application "Photodynamic therapy comprising two light exposures at different wavelengths" (US Appl. No. 17/269,816) to its wholly owned subsidiary Biofrontera Bioscience GmbH. This patent covers several inventions related to a novel lighting technique for Photodynamic Therapy (PDT) treatment of dermatological skin disorders. **March 2022:**The US patent No. 11,235,169 for the BF-RhodoLED XL illumination device was previously issued to Biofrontera Inc. The company has announced that the device is now listed in the FDA publication "Approved Drug Products with Therapeutic Equivalency Evaluations, or the Orange Book. ## Report Scope | MARKET SIZE 2024 | 320.4(USD Million) | | --- | --- | | MARKET SIZE 2025 | 355.32(USD Million) | | MARKET SIZE 2035 | 900.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.84% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Photocure ASA (NO), Merck & Co., Inc. (US), Galderma S.A. (CH), Sensus Healthcare, Inc. (US), DUSA Pharmaceuticals, Inc. (US), Aduro Biotech, Inc. (US), Curelight Ltd. (IL), OncoSec Medical Incorporated (US) | | Segments Covered | Application, Type of Photosensitizer, End User | | Key Market Opportunities | Advancements in light-activated drugs enhance treatment efficacy in the US Photodynamic Therapy Market. | | Key Market Dynamics | Growing regulatory support and technological advancements drive the expansion of the US Photodynamic Therapy Market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US Photodynamic Therapy Market?** A: As of 2024, the US Photodynamic Therapy Market was valued at 320.4 USD Million. **Q: What is the projected market size for the US Photodynamic Therapy Market by 2035?** A: The market is projected to reach 900.0 USD Million by 2035. **Q: What is the expected CAGR for the US Photodynamic Therapy Market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 9.84%. **Q: Which application segment is anticipated to dominate the US Photodynamic Therapy Market?** A: The Oncology segment is expected to dominate, with a valuation projected to grow from 128.0 USD Million to 360.0 USD Million. **Q: How does the Dermatology segment perform in the US Photodynamic Therapy Market?** A: The Dermatology segment was valued at 80.0 USD Million in 2024 and is projected to reach 220.0 USD Million by 2035. **Q: What types of photosensitizers are utilized in the US Photodynamic Therapy Market?** A: Key types of photosensitizers include Porphyrins, Phthalocyanines, Bacteriochlorophylls, and Synthetic Dyes, with Synthetic Dyes projected to grow from 120.4 USD Million to 330.0 USD Million. **Q: Which end-user segment is expected to show significant growth in the US Photodynamic Therapy Market?** A: Hospitals are anticipated to show significant growth, with a valuation expected to rise from 128.16 USD Million to 360.0 USD Million. **Q: Who are the key players in the US Photodynamic Therapy Market?** A: Key players include Photocure ASA, Merck & Co., Inc., Galderma S.A., and Sensus Healthcare, Inc. **Q: What is the projected growth for the Cardiology segment in the US Photodynamic Therapy Market?** A: The Cardiology segment is projected to grow from 60.0 USD Million to 180.0 USD Million by 2035. **Q: How does the market for Dental Clinics compare to other end-user segments?** A: The Dental Clinics segment is expected to grow from 64.08 USD Million to 180.0 USD Million, indicating a competitive position among end-user segments. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/united-states-photodynamic-therapy-market-20700*